A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics,and Efficacy of Nedosiran in Pediatric Patients from Birth to 5 Years of Age with Primary Hyperoxaluria Type 1 or Type 2 and Relatively Intact Renal Function